Combination has impact in kidney cancer

An experimental cancer therapy that combines the Roche checkpoint antibody Tecentriq (atezolizumab) and Avastin (bevacizumab) met its co-primary endpoint of progression-free survival in a Phase 3 trial of patients with metastatic renal cell carcinoma.

Full text available to subscribers only. Click here for information on subscribing to MedNous.